Symbols

BCDA

Biocardia·NASDAQ

--(--)

BCDA fundamentals

BCDA Q4 2025 Earnings

Biocardia (BCDA) released its earnings on Mar 24, 2026: revenue was 0 (YoY -100.00%), met estimates; EPS was 0 (YoY +100.00%), beat estimates.

Revenue / YoY

-100.00%

EPS / YoY

+100.00%

Report date

Mar 24, 2026

BCDA Earnings Call Summary for Q4,2025

Phase III Trial Success: CardiAMP showed statistically significant reductions in left ventricular volumes (20 mL/m² and 15 mL/m²) in patients with elevated NT-proBNP, supporting subgroup targeting for FDA and PMDA submissions.
Upcoming Regulatory Milestones: Q-Submission to FDA and clinical consultation with PMDA expected to drive 2026 approvals, with potential for a shorter De Novo pathway.
Financial Stability: 2025 cash of $2.5 million and controlled expenses position BioCardia for continued clinical advancement with modest R&D growth in 2026.
Competitive Edge: CardiAMP’s minimally invasive delivery and subgroup-focused data differentiate it from surgical therapies, positioning it as a leading cell therapy for heart failure.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Biocardia (BCDA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Biocardia (BCDA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Biocardia (BCDA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Biocardia (BCDA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown